Aman U Buzdar Selected Research

Drug Therapy (Chemotherapy)

09/2008	Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
12/2007	Preoperative chemotherapy treatment of breast cancer--a review.
10/2007	Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
02/2007	Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
01/2007	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
11/2006	Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
09/2006	Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
09/2006	Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer.
07/2006	Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer.
06/2006	Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
02/2006	Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
12/2005	Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
11/2005	Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
10/2005	Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
06/2005	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
06/2005	Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
01/2005	Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
12/2004	Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
11/2004	Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
10/2004	Colitis in patients with breast carcinoma treated with taxane-based chemotherapy.
05/2004	T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
04/2004	Preoperative chemotherapy for breast cancer.
04/2004	Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
10/2003	Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
10/2003	Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
05/2003	Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection.
04/2003	Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
10/2002	Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience.
04/2002	A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.

Articles by Research Topic

Disease

54	Breast Neoplasms (Breast Cancer) 09/2008 - 01/2002
9	Carcinoma (Carcinomatosis) 06/2006 - 04/2003
5	Neoplasms (Cancer) 11/2006 - 07/2002
3	Neoplasm Metastasis (Metastasis) 12/2005 - 10/2005
1	Obesity 09/2008
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2007
1	Lobular Carcinoma 01/2005
1	Pneumonia (Pneumonitis) 11/2004
1	Colitis 10/2004
1	Male Breast Neoplasms (Male Breast Cancer) 06/2002

Drug/Important Bio-Agent (IBA)

11	Paclitaxel (Taxol)FDA LinkGeneric 01/2007 - 05/2002
7	Tamoxifen FDA LinkGeneric 11/2007 - 01/2002
7	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2006 - 01/2002
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2007 - 01/2002
5	Fluorouracil (Carac)FDA LinkGeneric 01/2007 - 01/2002
5	anastrozole (Arimidex)FDA Link 06/2006 - 06/2002
5	Aromatase InhibitorsIBA 11/2005 - 05/2003
4	letrozole (Femara)FDA Link 05/2007 - 02/2004
4	trastuzumab (Herceptin)FDA Link 01/2007 - 06/2005
3	Epirubicin (Ellence)FDA LinkGeneric 01/2007 - 06/2005
2	Epidermal Growth Factor Receptor (EGF Receptor)IBA 01/2007 - 06/2005
2	fulvestrant (Faslodex)FDA Link 09/2006 - 09/2004
2	Estrogens (Estrogen)FDA Link 09/2004 - 02/2004
1	Epothilones (Epothilone)IBA 03/2008
1	Aromatase (CYP19)IBA 02/2008
1	LY 353381 (LY353381)IBA 11/2007
1	HormonesIBA 05/2006
1	Triethylenetetramine (Trien)IBA 02/2006
1	taxaneIBA 10/2004
1	TaxoidsIBA 07/2004
1	Protein Kinases (Protein Kinase)IBA 02/2004
1	Amantadine (Aman)FDA LinkGeneric 01/2004
1	RNA (Ribonucleic Acid)IBA 06/2003
1	Estrogen ReceptorsIBA 03/2003

Therapy/Procedure

29	Drug Therapy (Chemotherapy) 09/2008 - 04/2002
5	Adjuvant Chemotherapy 05/2007 - 05/2002
5	Mastectomy (Mammectomy) 07/2006 - 07/2002
3	Neoadjuvant Therapy 01/2008 - 06/2005
1	Aftercare (After-Treatment) 02/2004
1	Hematopoietic Stem Cell Transplantation 05/2003